Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

This study tests two drug combinations for women with advanced or metastatic breast cancer who carry a BRCA gene mutation (an inherited change that increases cancer risk). The study pairs olaparib (a PARP inhibitor — a drug that blocks cancer cells from repairing their DNA) with either cediranib or AZD6738 to see if the combination works better than olaparib alone. **You may be eligible if...** - You are a woman over 18 with advanced HER2-negative breast cancer and a BRCA gene mutation - You have received prior PARP inhibitor therapy and have been on it for at least 2 months before progression - Your organ function is adequate - You are not pregnant and willing to use contraception **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have untreated or symptomatic brain metastases - You have a history of heart attack, stroke, or severe heart conditions within the past 6–12 months - You have another cancer diagnosed within the past 5 years - You cannot swallow pills or absorb oral medications properly Talk to your doctor to see if this trial is right for you.